1014645-75-0

Basic information

• Product Name: 4-(1-aMinocyclopropyl)benzonitrile
• Synonyms: 4-(1-aMinocyclopropyl)benzonitrile
• CAS NO: 1014645-75-0
• Molecular Formula: C₁₀H₁₀N₂
• Molecular Weight: 158.1998
• Mol File: 1014645-75-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(1-aMinocyclopropyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-aMinocyclopropyl)benzonitrile(1014645-75-0)
• EPA Substance Registry System: 4-(1-aMinocyclopropyl)benzonitrile(1014645-75-0)

Safety Data

• Hazardous Substances Data: 1014645-75-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(1-aminocyclopropyl)benzonitrile is utilized as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs. Its unique structural features facilitate the creation of diverse chemical entities with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(1-aminocyclopropyl)benzonitrile serves as a versatile intermediate for the synthesis of agrochemicals, including pesticides and other bioactive compounds, due to its capacity to be incorporated into molecules with specific biological activities aimed at crop protection and enhancement of agricultural yields.
Used in Medicinal Chemistry Research:
4-(1-aminocyclopropyl)benzonitrile is employed as a subject of interest in medicinal chemistry research to explore its potential in the design and synthesis of novel bioactive molecules. Its unique structural elements offer opportunities for the discovery of new chemical entities with improved pharmacological properties and therapeutic potential.
Used in Drug Development:
As a chemical intermediate, 4-(1-aminocyclopropyl)benzonitrile is used in drug development for the creation of new pharmaceutical agents. Its presence in molecular structures can influence pharmacokinetics, pharmacodynamics, and overall drug efficacy, making it a valuable component in the advancement of medicinal compounds.

Upstream product

• 623-26-7 terephthalonitrile 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 1014645-83-0 4-(1-aminocyclopropyl)benzoic acid hydrochloride 
• 1618648-00-2 {1-[4-(tert-butoxycarbonylaminomethyl)phenyl]cyclopropyl}carbamic acid benzyl ester 
• 1618647-99-6 [1-(4-cyanophenyl)cyclopropyl]carbamic acid benzyl ester 
• 1380752-32-8 tert-butyl (1-(4-(1H-tetrazol-5-yl)phenyl)cyclopropyl)carbamate 
• 1338243-87-0 tert-butyl (1-(4-cyanophenyl)cyclopropyl)carbamate 
• 1014645-79-4 N-[1-(4-cyanophenyl)cyclopropyl]-2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]thiophene-3-carboxamide 

Relevant articles and documents

SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI

The present invention relates the compounds of the formula I, or the N-oxides, or the agriculturally acceptable salts thereof and to their use for combating phytopathogenic harmful fungi, wherein the variables are defined as given in the description and c

BENZYLAMINE DERIVATIVES

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.

Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl) amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP 4 antagonist for treating inflammatory pain

The discovery of a highly potent and selective EP4 antagonist MF-766 is discussed. This N-benzyl indole derivative exhibits good pharmacokinetic profile and unprecedented in vivo potency in the rat AIA model.

The discovery of 4-{l-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]- 3thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin e2 subtype 4 receptor antagonist

The discovery of highly potent and selective second generation EP4 antagonist MK-2894 (34d) is discussed. This compound exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti-inflammatory activity in several animal models of pain/inflammation. It also shows favorable GI tolerability profile in rats when compared to traditional NSAID indomethacin.

INDOLE AND INDOLINE CYCLOPROPYL AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Ph

THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS

The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoi